Hair shedding at month three: mechanism and time course — the long version posts 31–55

For anyone arriving from a search: the marked solution above is the direct answer, and the replies underneath it add the caveats that make it safe to use.

Coming back to post #30, because the follow-up matters more than the original answer.

Pancreatitis: a rare but serious event with a specific presentation (epigastric pain, back pain, elevated lipase). If this constellation of findings appears, stopping the drug and seeking immediate evaluation is appropriate. Do not interpret this as "likely" — it is rare — but recognize the pattern if it appears.

post #32 answers the question as asked. The question underneath it is different.

Delayed gastric emptying: the mechanism behind much of the gastrointestinal side-effect profile. At extreme magnitudes, severe gastroparesis is a rare but serious complication. Distinguishing ordinary gastrointestinal effects from the rare severe end is a clinical judgement.

Recognition and grading: nausea ranges from "noticeable" to "limiting". Constipation ranges from mild to severe. Having language to describe the magnitude helps you track whether something is worsening or stable and helps your clinician understand what you are reporting.

Timeline matters: onset, duration, pattern over days or weeks, relationship to injection and to meals all provide information that "I have nausea" does not. Posting those details gets better responses than reporting the symptom alone.

Nausea: the most common side effect and the most dose- and titration-dependent one. It is usually most prominent in the first 24 to 48 hours after injection and attenuates as the dose is held stable. At each escalation step it often resets briefly before attenuating again.

post #36 is right about the mechanism and I think understates the practical bit.

Constipation: common, manageable, and frequently under-reported because it is not dramatic. Increasing fibre and fluid intake helps. Over-the-counter management is usually effective. This is worth addressing proactively rather than waiting for it to worsen.

Worth separating two things that post #34 runs together.

Vomiting: when it is expected (first-dose reactions or early titration) and when it is a reason to stop and seek help are different. Occasional vomiting during titration is ordinary. Persistent vomiting or vomiting of a new character later in treatment warrants contact with your clinician.

Injection site reaction: local erythema, nodules, or induration at injection sites is reported by some people. Site rotation, avoiding reinjection into the same area for weeks, and allowing areas that react to recover all reduce the frequency.

Fatigue: commonly reported, frequently multifactorial. It is worth asking whether other factors have changed (sleep, training volume, diet adequacy, hydration) before attributing all of it to the compound. Some fatigue resolves with time; some persists.

I read post #39 twice before replying, because I had assumed the opposite.

Gallbladder complications: rapid weight loss increases the risk of gallstone formation. The mechanism is not specific to this drug class. The risk is greatest in the first months when weight loss is most rapid.

Gallbladder complications: rapid weight loss increases the risk of gallstone formation. The mechanism is not specific to this drug class. The risk is greatest in the first months when weight loss is most rapid.

Two things before anyone answers the substance.

First, the context in the first post is clear and specific. Second, the question is framed so that an answer can actually address it. Both are the norm here and both matter more than they sound.

post #43 is right about the mechanism and I think understates the practical bit.

Delayed gastric emptying: the mechanism behind much of the gastrointestinal side-effect profile. At extreme magnitudes, severe gastroparesis is a rare but serious complication. Distinguishing ordinary gastrointestinal effects from the rare severe end is a clinical judgement.